

What is claimed is:

1. A method of treating pain caused by neuralgia comprising administering botulinum toxin to an afflicted area of a patient.

2. The method of claim 1, wherein the pain is caused by trigeminal neuralgia.

N 3. The method of claim 1, wherein the pain is facial pain.

N 4. The method of claim 1, wherein the neuralgia is associated with compressive forces on a sensory nerve.

N 5. The method of claim 1, wherein the neuralgia is associated with intrinsic nerve damage, demyelinating disease, or a genetic disorder.

N 6. The method of claim 1, wherein the neuralgia is associated with a metabolic disorder.

N 7. The method of claim 1, wherein the neuralgia is associated with central neurologic vascular disease.

8. The method of claim 1, wherein the neuralgia is associated with trauma.

9. The method of claim 1, wherein the botulinum toxin is administered in a dose of from 10 to 200 LD 50 units.

N 10. The method of claim 1, wherein the pain is associated with dental extraction or reconstruction.

11. The method of claim 1, wherein the botulinum toxin is selected from the group consisting of immunotypes A-G.

N 12. A method of treating post-operative incisional wound pain comprising administering botulinum toxin to an afflicted area of a patient.

N 13. The method of claim 12, wherein the pain is associated with medical treatments selected from the group consisting of sinus surgery, removal of an eye, temporal mandibular joint surgery, parotid gland extraction and resection, craniotomy for removal of an intracranial tumor, intra-ocular surgery, acoustic neuroma surgery, reconstructive procedures after tumor resection, radiation therapy for the treatment of cancer, skull base surgery, orbitectomy, facial bone removal, muscle removal, skin removal, and construction of myocutaneous flaps.

14 14. The method of claim 12, wherein the botulinum toxin is selected from the group consisting of immunotypes A-G.

N 15 15. The method of claim 6, wherein the metabolic disorder is selected from the group consisting of diabetes and amyloidosis.

203010-010300

Rule  
1.126